Amgen Presents New Data of Repatha (Evolocumab) Including VESALIUS-CV Analysis in CKD at AHA 2026

Shots: Amgen has presented new data of Repatha (evolocumab) at AHA 2026, incl. a pre-specified P-III VESALIUS-CV analysis in high-risk patients with CKD & no prior heart attack or stroke In CKD patients, Repatha reduced 3-P MACE by 39%, 4-P MACE by 23% & all-cause death by 29% over a median follow-up of 4.6yrs; an independent VESALIUS-CV analysis found Repatha cost-effective at ~36% below the ACC/AHA benchmark A FOURIER & its OLE vs UK external control analysis showed Repatha was associated with 29% lower 3-P MACE & 25% lower CV death risk over a max. follow-up of >8yrs Ref: Amgen  |   Image: Amgen  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Amgen Presents New Data of Repatha (Evolocumab) Including VESALIUS-CV Analysis in CKD at AHA 2026 appeared first on PharmaShots.